Immunotech Biopharm Ltd (HKG:6978)
Hong Kong · Delayed Price · Currency is HKD 3.390
-0.240 (-6.61%)
Apr 17, 2026, 4:08 PM HKT
Immunotech Biopharm Market Cap
Immunotech Biopharm has a market cap or net worth of 2.24 billion as of April 17, 2026. Its market cap has decreased by -1.67% in one year.
Market Cap
2.24B
Enterprise Value
2.56B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
3.39
Market Cap Chart
Since July 10, 2020, Immunotech Biopharm's market cap has decreased from 7.74B to 2.24B, a decrease of -71.04%. That is a compound annual growth rate of -19.33%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 2.24B | 23.89% |
| Dec 31, 2025 | 1.81B | 52.87% |
| Dec 31, 2024 | 1.18B | -54.00% |
| Dec 29, 2023 | 2.57B | 7.99% |
| Dec 30, 2022 | 2.38B | -72.51% |
| Dec 31, 2021 | 8.67B | 50.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Jul 10, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 3.15B |
| Medtide | 3.13B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 2.61B |
| SinoMab BioScience | 2.34B |
| HighTide Therapeutics | 2.11B |
| Frontage Holdings | 2.09B |
| Mabpharm | 1.79B |
| Cutia Therapeutics | 1.73B |